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ABSTRACT The majority of fluorinated pharmaceutical products bear structurally simple fluoro- 
and trifluoromethyl-aromatic subunits, in part, due to the ready availability of a wide range of 
fluoro and trifluoromethyl aryl derivatives for both drug discovery and manufacturing campaigns. 
As life-science programmes are increasingly seeking more three-dimensional structures as hit-to-
lead compounds, the requirement for complex organic molecules bearing fluorine attached to sp3 
carbon in aliphatic systems and monofluorinated heterocycles is becoming more important. 
Consequently, the incorporation of new polyfunctional fluorinated building blocks into drug 
discovery projects is required, to drive the development of new generations of fluorinated 
pharmaceuticals in much the same way as the availability of fluorinated aromatic systems did in the 
past. Fluoromalonate esters are potentially very versatile fluorine containing building blocks that 
may be used for the introduction of fluorine atoms into aliphatic and heteroaromatic systems. The 
syntheses of fluoromalonate derivatives using commercially available fluorinating reagents on both 
research and manufacturing scales are described and the use of fluoromalonates for appropriate 
alkylation, acylation, Michael addition, annelation and biotransformation processes are presented, 
providing an indication of the synthetic possibilities available for accessing novel selectively 
fluorinated structures. 
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1. Introduction  
In 1952, Fried and Sabo published their seminal paper concerning the enhanced biological activity 
possessed by a fluorocortisoid derivative compared to both the parent and corresponding 
halogenated steroid systems.
1
 This discovery gave added impetus to the development of 
methodology for the introduction of fluorine atoms into organic systems and, today, around 20% of 
commercially significant pharmaceuticals and 30 % of all agrochemicals contain fluorinated groups 
within their structures that perform a variety of functions such as increasing metabolic stability, 
increasing lipophilicity and bioavailability.
2
 
Analysis of the 140 fluorine containing active pharmaceutical ingredients that have been approved 
for general use by the FDA since the 1950’s shows that by far the most common fluorinated motifs 
present in pharmaceutical structures
3
 are fluoroaromatic sub-units, principally 4-fluorophenyl (e.g. 
Atorvastatin (Lipitor), Ezetimibe (Zetia), Escitalopram (Lexapro) etc.) and trifluoromethyl aryl 
systems (e.g. Fluoxetine (Prozac), Dutasteride (Avodart), Travoprost (Travatan Z), etc.) (Fig. 1).  
 
FIGURE 1. Fluorine containing motifs in FDA approved active pharmaceutical ingredients (1950-
present)  
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Both fluoro and trifluoromethyl aromatic derivatives are synthesised on the large scale using 
anhydrous hydrogen fluoride for the key carbon-fluorine bond forming stage and usually in the 
early stages of the synthetic construction of the pharmaceutical product by commodity chemical 
manufacturers. Both Balz-Schiemann
4
 and Swart’s halogen exchange5 processes are very well 
developed for the manufacture of a wide range of fluoro and trifluoromethyl aromatic building 
blocks respectively. 
As the pharmaceutical industry seeks to further develop new pharmaceuticals that have more three-
dimensional structure in design strategies that are moving away from aromatic ‘flatland’,6 
methodology for the incorporation of fluorine atoms located at sp3 centres is gaining in importance. 
The major class of fluoroaliphatic pharmaceuticals are the anti-inflammatory fluorosteroids (18 out 
of 21 in the example set) such as Fluticasone propionate (Advair) and Difluprednate (Durezol).
3
 
Reagents such as DAST and Selectfluor
TM
 are now used widely in drug discovery programmes
2,7 
and, consequently, a wider range of fluorinated aliphatic motifs are being incorporated into drug 
design. Of course, the ready availability of polyfunctional, stable fluorinated aliphatic building 
blocks that have established, robust chemistry
8
 will further aid discovery and manufacturing 
campaigns and, in time, widen the types of fluorinated structural units in pharamaceuticals beyond 
mainly existing fluorinated aromatic derivatives.  
This review considers the synthesis and subsequent chemistry of polyfunctional, selectively 
fluorinated dialkyl fluoromalonate esters as substrates for the preparation of structurally more 
sophisticated fluorine containing systems, with a particular emphasis on fluorinated derivatives 
where fluorine is attached to sp3 carbon. Of course, the chemistry of non-fluorinated malonic esters 
is very well developed
9
 and a wide range of, for example, alkylation, acylation, Knoevenagel, aldol, 
reduction, Michael addition, nucleophilic substitution and annelation processes are utilised in many 
important syntheses. Malonate esters frequently appear in restrosynthetic planning strategies
10
 from 
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University sophomore classes onwards. In comparison, however, corresponding chemistry of 
dialkyl fluoromalonate esters is not developed to any great extent and the relatively few patents 
using diethyl fluoromalonate as a fluorinated building block for the synthesis fluorinated 
biologically active systems have only begun to appear in the past 10 years (Fig. 2), providing an 
indication of the relatively undeveloped potential of these polyfunctional selectively fluorinated 
systems. 
 
FIGURE 2. Diethyl fluoromalonate esters in patents (2000-present) 
 
The relatively recent developments in fluoromalonate chemistry is most probably due to the recent 
commercial availability of dimethyl and diethyl fluoromalonate at very reasonable prices from the 
usual speciality chemical suppliers. No special handling procedures are required when using 
fluoromalonate esters for synthetic processes beyond employing the usual laboratory and industrial 
safety precautions. 
Here, we discuss the synthesis of fluoromalonate esters and the use of these potentially versatile 
fluorinated substrates as fluorinated-building blocks in synthesis to aid synthetic strategy planning 
for the preparation of fluorinated derivatives that will provide opportunities to access new 
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fluorinated chemical space for life-science applications, in particularly systems where fluorine is 
attached to sp3 carbon in aliphatic systems. 
 
2. Synthesis of dialkyl 2-fluoromalonate esters 
2.1 Electrophilic fluorination of malonate enol derivatives 
Replacement of enolic hydrogen atoms by fluorine using an electrophilic fluorinating agent offers 
the most direct method for the synthesis of fluoromalonate esters and, over the last 60 years, several 
procedures have been developed using the fluorinating reagents available at the time. The first 
example of fluorination of malonate esters using perchloryl fluoride (FClO3) was published in 
1958.
11
 When FClO3 was passed through an ethanolic solution of sodium diethyl malonate, a 50 : 50 
mixture of diethyl malonate and diethyl 2,2-difluoromalonate was obtained rather than the expected 
diethyl 2-fluoromalonate while two equivalents of NaOEt and FClO3 gave pure diethyl 2,2-
difluoromalonate in high yield. Fluorination of a small range of 2-substituted malonic esters gave 
the corresponding fluoromalonate product (Scheme 1a) but this fluorination methodology was not 
widely adopted because of the highly oxidising and potentially explosive nature of perchloryl 
fluoride. 
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SCHEME 1. Initial processes for the synthesis of 2-fluoromalonate esters using (a) FClO3; (b) 
acetyl hypofluorite; (c) N-fluoropyridone; (d) N-fluoro-N-alkylsulfonamide; (e) benz-1,2,3-
oxathiazin-4-(3-F)-one 2,2-dioxide. 
 
In the 1980’s, the development of novel electrophilic fluorinating reagents of the O-F and N-F class 
allowed the synthesis of a wider range of 2-fluoro-1,3-dicarbonyl systems. Acetyl hypofluorite 
(CH3COOF), developed by Rozen, was the first successful reagent to monofluorinate 1,3-
dicarbonyl systems in reasonable yield and purity (Scheme 1b).
12
 
N-Fluoro-2-pyridone can conveniently be prepared from 2-trimethylsiloxy pyridine with elemental 
fluorine (5% in N2)
13
 and is capable of fluorinating sodium dialkyl malonates, but yields are poor, 
reaching only 39% in the case of diethyl 2-phenylmalonate (Scheme 1c). N-Fluoro-N-
alkylsulfonamides, introduced by Barnette
14
 in the early 1980s, are prepared by passing dilute (3-5 
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% in N2) fluorine gas through a solution of the corresponding sulfonamide in an inert solvent. Their 
fluorinating power was demonstrated by reaction with a series of carbanion sytems, most of which 
gave the desired monofluorinated product in good yield (Scheme 1d).
14
  Similarly, DesMarteau 
synthesised a range of N-fluoro-perfluoroalkylsulfonimides
15
 from elemental fluorine. These 
reagents readily react with carbanionic substrates and essentially give the fluorinated product in 
quantitative yield (96 % for diethyl 2-methylmalonate) but their hazardous preparation (use of neat 
fluorine that is liquefied during the reaction) precludes widespread use of these reagents. More 
recently another class of N-fluorosulfonamide was developed that uses oxathiazione dioxides as 
easily accessible starting materials.
16
 The most stable and promising fluorinating reagent is benz-
1,2,3-oxathiazin-4-(3-F)-one 2,2-dioxide which fluorinates various carbon nucleophiles (Scheme 
1e). Similarly, for the fluorination of carbanions, N-fluoro-2,4,6-trimethylpyridinium triflate 
(trifluoromethanesulfonate) was found to react with the diethyl malonate sodium salt to give diethyl 
2-fluoromalonate and other, substituted malonates provided access to the corresponding fluorinated 
products in high yield.
17
 
In the past few years, N-fluorobenzenesulfonimide (NFSI) and Selectfluor
TM
 have emerged as the 
most effective electrophilic fluorinating reagents of the N-F class because they are shelf stable, 
solid, commercially available reagents that do not require any additional handling procedures 
beyond the usual precautions taken in a research laboratory. N-Fluorobenzenesulfonimide (NFSI) is 
used for the asymmetric fluorination of prochiral malonate esters
18
 (Scheme 2) and reaction of 
Selectfluor
TM
 with diethyl 2-phenylmalonate salt afforded fluorinated product in almost quantitative 
yield (93 %)
19
. Similarly, several fluoromalonate derivatives have been prepared using 
Selectfluor
TM
, for use as liquid crystal compounds
20
 and potential pharmaceutical targets (Scheme 
2).
21
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SCHEME 2. Synthesis of fluoromalonates using N-fluorobenzenesulfonimide (NFSI) and 
Selectfluor
TM
. 
 
The direct fluorination of malonates with elemental fluorine gas was believed to be impractical until 
it was demonstrated by Purrington that it is possible to selectively fluorinate trimethylsilyl-malonate 
derivatives.
22
 The starting material in this case was the corresponding silyl enol ether that was 
fluorinated with dilute (5% in N2) fluorine gas in an inert Freon solvent (Scheme 3a). The use of 
elemental fluorine for the synthesis of fluoromalonate esters was further developed by Chambers.
23
 
Fluorination of several dialkyl sodio-malonates in acetonitrile solution gave a product mixture that 
contains mono and difluorinated product and their relative ratio depends upon the number of base 
equivalents used. With one equivalent of NaH, 37 % mono- and 23 % difluorinated malonate esters 
were obtained while when adding 2.25 equivalents of NaH, the difluorinated product was the major 
product (37 %) with 14 % monofluoro malonate. Substituted dialkyl malonate salts react with 
elemental fluorine to provide high yields of the corresponding fluorinated derivatives (Scheme 
3b).
23
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SCHEME 3. Synthesis of fluoro malonate esters using fluorine gas.  
 
Fluorination of diethyl malonate in a continuous flow microreactor using acetonitrile as reaction 
medium gave several mono- and difluorinated products but with low selectivity.
24
 The change of 
substrate to Meldrum’s acid (2,2-dimethyl-1,3-dioxane-4,6-dione) followed by treatment of the 
crude reaction mixture with ethanol before the work-up stage gave mono- and difluoromalonate  
derivatives which could be easily separated (Scheme 3c). However, the selectivity problem for 
direct fluorination of malonate substrates was solved when it was discovered that the addition of a 
catalytic amount of copper nitrate (Cu(NO3)2.2.5 H2O) could activate the malonate substrate 
towards direct fluorination (Scheme 3d).
25
 As an alternative approach, dialkyl 2-formyl malonates 
10 
 
readily react with elemental fluorine to yield dialkyl 2-fluoro-2-formyl malonates that can easily be 
deformylated to yield exclusively the monofluorinated product in good yield (Scheme 3e).
26
   
 
2.2 Halogen exchange reactions 
Halogen exchange of chlorine by fluorine using a suitable source of fluoride ion offers an 
alternative approach to the synthesis of fluoromalonate derivatives. In the early 2000s’ several 
patents were filed by Bayer
27
 and Solvay
28
  concerning reactions of base and amine-hydrogen 
fluoride complexes with diethyl chloromalonate (Scheme 4). 
 
 
SCHEME 4. Synthesis of fluoromalonates by Halogen exchange processes. 
 
Bayer’s procedure uses triethylamine and triethylamine.3HF to give diethyl 2-fluoromalonate in 82 
% yield while Solvay’s process uses DBN (1,5-diazabicyclo[4.3.0]non-5-ene) HF complex as the 
fluoride ion source to give diethyl 2-fluoromalonate in 91% conversion on a large scale, as stated in 
the relevant patent descriptions.  
 
2.3 Miscellaneous preparations  
11 
 
The condensation of fluoroacetic acid derivatives with alkyl chloroformate is another possible route 
for the synthesis of dialkyl fluoromalonate derivatives.
29
 In an early procedure, ethyl chloroformate 
and the sodium enolate of ethyl fluoroacetate gave diethyl 2-fluoromalonate in low yield (21 %). A 
similar procedure was developed using less toxic ethyl bromofluoroacetate
30
 which was reacted 
with tributylphosphine to form an ylid that was acylated using ethyl chloroformate, to give diethyl 
2-fluoromalonate (Scheme 5). 
 
 
SCHEME 5. Acylation of ethyl bromofluoroacetate.  
 
A method involving sequential solvolysis of hexafluoropropene to give dialkyl 2-fluoromalonates in 
good yield was published by Japanese authors in the early 1980s (Scheme 6).
31
 Since 
hexafluoropropene (HFP) is manufactured on a very large scale for the production of various 
fluoropolymers, it is an inexpensive starting material. When HFP is reacted with an alcoholic 
solution of sodium alkoxide conjugate addition of an alcohol leads to an ether that can be 
hydrolysed by concentrated sulfuric acid to give alkyl 2,3,3,3-tetrafluoropropanoate. When this 
ester is reacted with an alcoholic sodium alkoxide solution, HF elimination gives the corresponding 
acrylic acid derivative that immediately undergoes further substitution followed by acidic 
hydrolysis to give the desired dialkyl fluoromalonate. 
12 
 
 
SCHEME 6. Sequential solvolysis of hexafluoropropene.
31b
 
 
In summary, simple fluoromalonate derivatives such as dimethyl and diethyl fluoromalonate are 
synthesised on a large scale using halogen exchange or hydrolysis processes described above and 
are available at reasonable prices from the usual chemical suppliers. More complex fluoromalonate 
systems, particularly for research scale processes, may be synthesised most readily by reaction of 
the corresponding malonate with either NFSI or Selectfluor
TM
, thus providing access to a wide 
range of fluoromalonate building blocks to all laboratories for life-science applications. 
 
3. Reactions of fluoromalonate ester derivatives 
3.1 Reactions with carbon electrophiles  
The alkylation of fluoromalonate esters using simple alkyl halides as electrophiles may be mediated 
using sodium ethoxide in ethanol but, predictably, alkylation proceeds more slowly than the non-
fluorinated malonate due to the lower stability and nucleophilicity of the fluoromalonate ion. 
Dialkyl fluoromalonates are alkylated
32
  in the syntheses of a carbopeptidase U inhibitor
33
 and 
enzymatically triggered chemiluminescent probes.
34
 Similarly, synthesis of bicyclo[3.1.0]hexane 
based anti-anxiety drug candidates involves a related early stage epoxide opening step35,36
 
with 
diethyl fluoromalonate as the substrate (Scheme 7). Ring opening of aziridines by reaction of 
fluoromalonate anions provides a useful method for the synthesis of -fluoro--amino acids after 
appropriate deprotection.
37
 While related ring opening of -lactone derivatives gives access to -
fluoro-dicarboxylic acids.
38
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SCHEME 7. Alkylation of fluoromalonate derivatives. 
Palladium catalysed allylation of fluoromalonate can also be utilised for the attachment of allyl 
groups to the fluorinated carbon centre.
39
  
 
 
SCHEME 8. Palladium catalysed allylation of fluoromalonate. 
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Related reaction of fluoromalonate with formaldehyde has been used for the synthesis of fluorinated 
acrylic ester monomers
40
 in which 2-fluoroacrylic chloride was prepared in three steps from 
dimethyl 2-fluoromalonate (Scheme 9). Similar synthesis of related 2-fluoroacrylate derivatives was 
used for the preparation of fluorinated porphobilinogens.
41
  
 
 
SCHEME 9.  Synthesis of 2-fluoroacrylic chloride form dimethyl fluoromalonate.
  
 
Addition of 2-fluoromalonate anions to C=N bonds lead to α-fluoro-β-aminoacid precursors which 
are effectively generated from aldimines or their synthetic equivalents. A simple synthesis of 
racemic 2-fluoro-2-(α-Cbz-aminobenzyl)malonates used diethyl fluoromalonate and α-amido p-
tolylsulphones as the Mannich base equivalent reagents
42
 while enantioselective addition of diethyl 
fluoromalonate to N-Boc aldimines was performed using a chiral thiourea based organocatalyst 
(Scheme 10).
43
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SCHEME 10.  Reaction of fluoromalonate with C=N bonds. 
A very efficient 2-fluoroacrylate ester synthesis is based on a domino reaction where the first step is 
the addition of fluoromalonate to an -unsaturated ketone followed by elimination to give a 
fluoroacrylate derivative.
44
 Although the yields vary from poor to excellent, the E/Z selectivity of 
the reaction is very good (Scheme 11).  
 
 
 
SCHEME 11.  Synthesis of fluoroacrylates from fluoromalonates.  
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Of all the possible reactions of fluoromalonate systems, enantioselective addition of dialkyl 
fluoromalonate derivatives to different Michael-acceptors has attracted the most attention. The first 
reported example described the use of an efficient cinchonine derived quaternary ammonium salt 
catalyst for addition of fluoromalonate to chalcone derivatives but, unfortunately, the 
enantioselectivty was mediocre.
45
 Similarly, the enantioselective addition of diethyl fluoromalonate 
to α,β unsaturated aldehydes was carried out in the presence of a simple prolinol organocatalyst that 
proceeded in good yield and enantiopurity (Scheme 12).
46
 
 
 
 
SCHEME 12.  Enantioselective Michael addition of diethyl fluoromalonate to -unsaturated 
carbonyl derivatives.  
 
Nitroalkenes are Michael-acceptors that are often used in the testing of novel chiral catalyst systems 
and, in 2009, three different catalysts were shown to be very effective for the addition of 
fluoromalonates to nitroalkene substrates
47-49 
(Scheme 13). 
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SCHEME 13.  Enantioselective addition of dialkyl fluoromalonates to nitroalkenes. 
 
Although the yields and enantiopurities are very similar, the nickel complex catalyst appears to be 
more effective than the organocatalysts for these addition reactions since the reaction times are 
significantly shorter and the catalyst load is lower (5 mol% vs 10 and 20). While the 
organocatalysts react slowly with related ortho-substituted benzene derivatives, the nickel catalyst 
is not found to be affected by steric effects. The absolute configuration of these products was found 
to be S in all cases. 
Michael addition of fluoromalonates to related systems have been used in the synthesis of several 
complex monofluorinated structures such as α-fluoro-γ-aminoacids37, 4-fluoroglutamates50 and 4-
fluoro-5,5’-dihydroxyleucine derivatives51, that find use as herbicides,52 immuno-modulators53 and 
potassium channel deactivator
54
 compounds (Scheme 14).  
18 
 
 
 
SCHEME 14. Michael addition reactions of fluoromalonates. 
 
Arylation by nucleophilic aromatic substitution processes involving reaction of fluoromalonate 
anion with 2-fluoronitrobenzene and nitrobenzyl bromide derivatives provides convenient access to 
unusual 3-fluoroxindole
55
 and 3-fluorotetrahydroquinolone
56
 derivatives respectively (Scheme 15).  
 
 SCHEME 15. Synthesis of 3-fluoroxindole and 3-fluorotetrahydroquinolone derivatives. 
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Using a more generally applicable procedure, palladium catalysed reactions allow cross-coupling of 
diethyl fluoromalonate with a variety of aryl bromides (Scheme 16).
57
 This methodology has 
already been employed for the synthesis of novel fluorinated arylamide derivatives that are potential 
cancer treatment drug candidates.
21a
 
SCHEME 16. Pd catalysed arylation of diethyl fluoromalonate.  
 
3.2 Functional group interconversion reactions 
Hydrolysis of one of the ester groups of fluoromalonate systems can be achieved by heating in 
aqueous acidic media enabling, for example, the simple synthesis of -fluorocarboxylic acid 
derivatives and, despite the simplicity of these reactions, only a few examples of this chemistry 
have been reported. Early publications discussed the synthesis of 2-fluoroalkanoic acids
12,38 
and 2-
fluoro-2-phenylacetic acid
22
 and several similar syntheses of bioactive compounds such as anti-
cancer system 2-fluoro-6-benzothiophenyl acetic acid,
21a,58
 2-aryl-5-fluoromethyl-1,3,4-oxadiazol
21b
 
derivatives, 3-aryldifluoromethylpyridazines
59
 and α-fluorovalerolactone containing steroids60 
(Scheme 17) have been reported in the patent literature.  
 
20 
 
SCHEME 17.  Acid hydrolysis of fluoromalonate systems. 
 
Possibly the only practical syntheses of 2-fluoro-1,3-propanediol derivatives are reductions of 
appropriate fluoromalonate derivatives using diborane in tetrahydrofuran
61
 or calcium 
borohydride.
62
 Similarly, fluoromalonates can be reduced to 2-fluoro-3-hydroxypropanoates if the 
monoester is first prepared by partial hydrolysis of the corresponding diesters (Scheme 18).
63
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SCHEME 18.  Reduction of fluoromalonate esters 
 
Malonamides and propane 1,3-diamines are practical building blocks for the synthesis of more 
complex structures such as heterocycles and macrocycles. The fluorinated analogues can easily be 
prepared from dialkyl fluoromalonates by reaction with amines and reduction as appropriate. An 
early example of this chemistry was the synthesis of several fluorinated cyclam (1,4,8,11-
tetraazacyclotetradecane) systems that form metal ion complexes.
64
 The incorporation of 2-fluoro- 
or 2,2-difluoro-1,3-diaminopropyl segments into complex bioactive structures such as potential 
antitumor,
65-67
 Alzheimer’s disease,68,69 cardiovascular disease,70 immunosuppressant activity,71 and 
enzyme inhibition
72
 systems. Similarly, fluorinated 1,4-benzodiazepines were successfully 
synthesised from diethyl fluoromalonates when reacted with appropriate 1,2-diaminobenzenes 
(Scheme 19).
31b,73 
 
SCHEME 19.  Synthesis of fluorinated diamides and cyclam.  
22 
 
Arguably, the most important applications of fluoromalonate derivatives are for the synthesis of 
different heterocyclic structures and the earliest fluoroheterocycle synthesis using diethyl 
fluoromalonate was the preparation of 2-ethylthio-5-fluoro-4,6-dihydroxypyrimidine by reaction of 
diethyl fluoromalonate with S-ethyl isothiouronium bromide.
29
 In 2009, a novel antibacterial drug 
family bearing a 5-fluoropyrimidine unit was patented by GSK.
74
 The synthesis of this drug family 
is based on condensation of dialkyl fluoromalonates with amidines followed by halogenation to 
give a 2-substituted 4,6-dichloro-5-fluoropyrimidine drivative that can be further functionalised 
using standard synthetic transformations. 4,6-Dihydroxypyrimidines can easily be converted to the 
corresponding dichloropyrimidines using phosphorus based halogenating reagents such as PCl3, 
POCl3 or PCl5.
75
 Fluoxastrobin, a commercially significant herbicide, is synthesised from 
fluoromalonate
76
 by Bayer CropScience by a similar strategy (Scheme 20). 
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SCHEME 20.  Synthesis of 5-fluoro-pyrimidine derivatives.  
 
Since 2005, several further pharmaceutical and agrochemical patents have described biologically 
active systems bearing the 5-fluoropyrimidine sub-unit within more complex systems. In most of 
these cases compounds are derived from 4,6-dichloro-5-fluoropyrimidine derivatives including 
Janus kinase inhibitor,
77
 orexin receptor modulator,
78
 anti-cancer,
79
 GPCR inhibitor,
80
 RAF kinase 
inhibitor,
81
 calcium channel antagonists
82
 and chronic obstructive pulmonary disease treatment 
systems.
83
 
Dimethyl 2-fluoromalonate was used in the large scale synthesis of 3-fluoroquinoline derivatives 
that were used in the synthesis of novel anti-bacterial drug candidates (Scheme 21).
84
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SCHEME 21. Synthesis of 3-fluoro-6-methoxyquinoline using dimethyl fluoromalonate.
84
  
 
A recent report from Takeda Pharmaceuticals discusses the synthesis of 3,5-disubstituted 6-fluoro-
8-methylpyrido[2,3-d]pyrimidine-4,7-(3H,8H)-diones which are active pharmaceutical ingredients 
used for the synthesis of various drug candidates (Scheme 22).
85
  
 
 
SCHEME 22. Synthesis of 6-fluoro-8-methylpyrido[2,3-d]pyrimidine-4,7-(3H,8H)-dione.  
 
3.3 Biotransformations for the synthesis of chiral fluorinated building blocks 
The first reported use of fluoromalonates for the synthesis of chiral building blocks was the 
enantioselective enzymatic hydrolysis of malonate esters to malonate monoesters
86
 using esterase 
(Candida Cylindracea) and cellulase (Trichoderma Viride) enzymes (Table 1). 
 
TABLE 1. Enzymatic asymmetric hydrolysis of fluoromalonates.
86
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Substrate Origin of enzyme Yield (%)  %ee 
MeCF(COOEt)2 Candida Cylindracea 87 (-) 91 
MeCF(COOEt)2 Trichoderma Viride 60 (+) 56 
MeCF(COOMe)2 Candida Cylindracea 74 (-) 95 
MeCF(COOMe)2 Trichoderma Viride 83 (+) 46 
EtCF(COOEt)2 Candida Cylindracea 87 (-) 93 
EtCF(COOEt)2 Trichoderma Viride No reaction - 
EtCF(COOMe)2 Candida Cylindracea 87 (-) 99 
EtCF(COOMe)2 Trichoderma Viride No reaction - 
CHF(COOEt)2 Candida Cylindracea 70 (+) 62 
CHF(COOEt)2 Trichoderma Viride 51 (+) 58 
n-PrCF(COOEt)2 Candida Cylindracea No reaction - 
n-BuCF(COOEt)2 Candida Cylindracea No reaction - 
 
The results clearly indicate that, with the selection of the appropriate enzyme, chiral fluoromalonate 
monoesters can be obtained in excellent yield and enantiopurity. Using appropriate enzymes, both 
enantiomers may be synthesised, but the lipase from Candida Cylindracea appears to be a more 
efficient catalyst for this transformation. The scope of this hydrolysis reaction is very limited 
because alkyl chains longer then ethyl completely inhibit the reaction due to steric inhibition. The 
absolute configurations were determined by reducing (+)-2-fluoromalonate monoethyl ester to the 
corresponding known R-ethyl 2-fluoropropionate.
87
 Substitution of a hydrogen atom by fluorine 
does not affect the highly stereo-controlled enzymatic reactions.
88
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A practical approach to asymmetric 2-aryl-2-fluoro-1,3-propanediol monoacetate derivatives was 
developed using enzymatic hydrolysis of 2-aryl-2-fluoromalonate esters.
89
 In these reactions, Celite 
supported porcine pancreatic lipase (S-PPL) was used for the asymmetric hydrolyses that ultimately 
led to 1-(O)-benzyl-2-aryl-2-fluoro-1,3-propanediol products with good enantiopurity. The substrate 
scope was later extended to 2-methoxy systems but in this case microbial lipase Amano AY, (AYL) 
was utilised (Scheme 23).
90 
 
  
 
SCHEME 23.  Asymmetric hydrolysis and decarboxylation of 2-substituted fluoromalonates.  
 
Enantiopure 2-fluoro-2-phenylacetic acid is used as a chiral derivatising agent to determine 
enantiomeric excess by 
19
F NMR.
91
 A very efficient and selective synthesis of (R)-2-fluoro-2-
phenylacetic acid was developed by Japanese researchers when an arylmalonate decarboxylase 
enzyme (expressed from E. coli JM 109) was used to decarboxylate dipotassium 2-fluoro-2-
phenylmalonate.
92
 The crude product of the reaction already was 99.1% pure R isomer, but after one 
recrystallization (69% recovery) enantiopure product was obtained. 
The first use of synthetic biology for the synthesis of fluorinated systems has been reported by 
Chang and co-workers. In this process, fluoromalonyl-CoA was used to synthesise fluorinated 
polyketides avoiding the use of highly toxic fluoroacetyl-CoA (Scheme 24).
93
 
27 
 
 
  
SCHEME 24. Synthesis of fluorinated polyketides 
 
4. Conclusions 
Fluoromalonate esters are readily synthesised on a large scale and a variety of transformations 
allowing the preparation of structurally more sophisticated fluoro-aliphatic and heterocyclic 
derivatives have been described. Given the importance of fluorine containing structural sub-units in 
pharmaceuticals and the synthetic versatility of fluoromalonate systems, it is perhaps surprising that 
only a relatively few publications and patents describing the chemistry of fluoromalonates have 
been reported.  This review has outlined the potential for the use of fluoromalonates in synthesis as 
a contribution to the development of new generations of fluorinated pharmaceuticals. 
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